Hui Xie
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 3
- Breast Cancer Treatment Studies 3
- Oncology top 10%
- Cancer Cells and Metastasis 6
- Immunology top 10%
- Obstetrics and Gynecology top 10%
- Molecular Biology top 10%
- Epigenetics and DNA Methylation 4
-
- SARS-CoV-2 detection and testing 4
-
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 4
- Renal cell carcinoma treatment 3
-
- Ultrasound and Hyperthermia Applications 3
- Co-authors
- Thomas L. RothsteinRuilan WangXiaoxiao MengYong ZhuJinfeng WangXiaoxiang GuanXiao‐Yan JiangYingyu Dou
- Cited by
- Cancer ResearchOncologyImmunology
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Hui Xie
54 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 120
- Cancer Research 318
- Oncology 360
- Immunology 270
- Obstetrics and Gynecology 84
- Molecular Biology 704
Countries citing papers authored by Hui Xie
This map shows the geographic impact of Hui Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Xie more than expected).
Fields of papers citing papers by Hui Xie
This network shows the impact of papers produced by Hui Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Xie. The network helps show where Hui Xie may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hui Xie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 1 | |
| 7 | 2022 | 0 | |
| 8 | 2021 | 10 | |
| 9 | 2021 | 3 | |
| 10 | 2020 | 40 | |
| 11 | 2020 | 80 | |
| 12 | 2019 | 19 | |
| 13 | 2018 | 11 | |
| 14 | 2017 | 9 | |
| 15 | 2017 | 6 | |
| 16 | 2017 | 8 | |
| 17 | 2016 | 13 | |
| 18 | 2013 | 15 | |
| 19 | 2013 | 39 | |
| 20 | 2007 | 10 |
About Hui Xie
Hui Xie is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 62 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (6 papers), SARS-CoV-2 detection and testing (4 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Epigenetics and DNA Methylation (4 papers), Renal cell carcinoma treatment (3 papers), Cancer Genomics and Diagnostics (3 papers), Ultrasound and Hyperthermia Applications (3 papers) and Breast Cancer Treatment Studies (3 papers). The work is most often cited by research in Cancer Research (318 citations), Oncology (360 citations) and Immunology (270 citations). Hui Xie has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Thomas L. Rothstein, Ruilan Wang, Xiaoxiao Meng, Yong Zhu, Jinfeng Wang, Xiaoxiang Guan, Xiao‐Yan Jiang, Yingyu Dou, Rui Tian and Wenbin Zhou. Their work appears in journals such as Nature Communications, The Journal of Immunology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.